Merck stopped developing MK-1484, but says it was routine pipeline prioritization, not a response to safety or efficacy. The report gives no sign this single program changes Merck's wider outlook.
One possible cancer treatment is now gone from Merck's research. The report says the choice was routine, not a response to safety or efficacy problems. It does not show a wider change in Merck's business outlook.
Sutro loses a partnered drug program after Merck ended MK-1484 development. Merck called the choice routine, not a safety or efficacy response, but the canceled program is still a setback for Sutro.
Follow Merck & Co. (MRK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRK